Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol

Introduction Illicit opioid use has become a national crisis in Canada, with over 65 000 people seeking treatment for opioid use disorder (OUD) in Ontario and British Columbia alone. Medication-assisted treatment (MAT) is a common treatment for OUD. There is substantial variability in treatment outcomes used to evaluate effectiveness of MAT, making it difficult to establish clinically and scientifically relevant treatment effect. Furthermore, patients are often excluded from the process of determining these outcomes. The primary objective of this review is to examine outcomes currently used to measure MAT effectiveness and to identify patient-relevant outcomes to enhance effectiveness of treatment options. This review refers to patient-important outcomes as those outcomes patients consider important to or markers of treatment success. Methods and analysis MEDLINE, EMBASE, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Cochrane Library, Cochrane Clinical Trials Registry, National Institutes for Health Clinical Trials Registry and WHO International Clinical Trials Registry Platform databases will be searched. We will search databases from inception to the date the search is ran. Studies of interest include those evaluating the effectiveness of MAT for patients with OUD, with or without consultation with patients regarding what they consider to be important as an indicator of treatment success. Results will be analysed using thematic analysis and qualitative analysis where possible. This will result in comprehensive synthesis of all outcomes and measures found related to OUD treatment effectiveness. Ethics and dissemination We are collaborating with Canadian Addiction Treatment Centres which provide MAT to patients with OUD who will participate in disseminating study results. Dissemination strategies will involve sharing study results through workshops, presentations, peer-reviewed publications, study reports, community presentations and resources in primary care settings. PROSPERO registration number CRD42018095553.

[1]  M. Farrell,et al.  Maudsley Addiction Profile , 2019 .

[2]  Evan Wood,et al.  Management of opioid use disorders: a national clinical practice guideline , 2018, Canadian Medical Association Journal.

[3]  G. Guyatt,et al.  The authors respond to “Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain” , 2017, Canadian Medical Association Journal.

[4]  M. Schuckit Treatment of Opioid-Use Disorders. , 2016, The New England journal of medicine.

[5]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2016, British Medical Journal.

[6]  Pavel S. Roshanov,et al.  Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria , 2015, Trials.

[7]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[8]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[9]  L. Møller,et al.  The effectiveness of opioid maintenance treatment in prison settings: a systematic review. , 2012, Addiction.

[10]  J. Kantelip,et al.  Interindividual Variability of Methadone Response , 2008, Molecular Diagnosis & Therapy.

[11]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[12]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[13]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[14]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[15]  J. Rehm,et al.  Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study) , 2005, Journal of Urban Health.

[16]  G. Bertschy Methadone maintenance treatment: An update , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[17]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[18]  M. Farrell,et al.  The Maudsley addiction profile: a brief instrument for treatment outcome research. Development and user manual. , 1998 .

[19]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.